Ashley Perry
Family · Gulfport, MSNPI 1013181486
Payments from drug & device makers
Across 494 payments — averaging $17.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- Abbott$1K
- Dexcom, Inc.$792
- Lilly USA, LLC$690
- Corcept Therapeutics$493
- Boehringer Ingelheim$430
- plus $4K from 33 others
What the payments were for
- Food & beverage$8,876100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 97 | $1,221 |
| Abbott | 51 | $1,169 |
| Dexcom, Inc. | 40 | $792 |
| Lilly USA, LLC | 42 | $690 |
| Corcept Therapeutics | 15 | $493 |
| Boehringer Ingelheim | 16 | $430 |
| Bayer | 19 | $428 |
| Medtronic | 26 | $392 |
| Xeris Pharmaceuticals, Inc. | 21 | $391 |
| Amgen | 24 | $347 |
| Sanofi-aventis U.S. LLC | 18 | $312 |
| AstraZeneca | 14 | $295 |
| GRT US Holding, Inc. | 18 | $292 |
| Merck | 9 | $184 |
| Averitas Pharma Inc. | 9 | $162 |
| BD | 6 | $134 |
| AbbVie | 8 | $129 |
| Radius Health, Inc. | 7 | $123 |
| Zealand Pharma US, Inc. | 6 | $102 |
| Clarus Therapeutics Inc. | 6 | $99 |
| Embecta Corp. | 4 | $72 |
| Vistapharm, Inc. | 4 | $61 |
| IBSA Pharma Inc. | 3 | $56 |
| Insulet Corporation | 3 | $55 |
| Lifescan, Inc. | 4 | $54 |
| Vifor Pharma, Inc. | 4 | $49 |
| Tandem Diabetes Care, Inc. | 2 | $46 |
| Ultragenyx Pharmaceutical Inc. | 2 | $41 |
| UCB, Inc. | 2 | $35 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $31 |
| Tolmar, Inc. | 2 | $28 |
| Ascendis Pharma Endocrinology Inc | 1 | $24 |
| Amneal Pharmaceuticals LLC | 2 | $23 |
| Acerus Pharmaceuticals Corporation | 1 | $20 |
| Rhythm Pharmaceuticals, Inc. | 1 | $18 |
| Alfasigma USA, Inc. | 1 | $16 |
| Novartis | 1 | $16 |
| Mannkind Corporation | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$228
- JARDIANCE$228
- FreeStyle Libre$115
- FARXIGA$109
How this compares
$8,876 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 122 | $127,579 |
| OzempicSemaglutide | 120 | $123,363 |
| MounjaroTirzepatide | 90 | $107,134 |
| Tresiba Flextouch U-200Insulin Degludec | 62 | $92,413 |
| TrulicityDulaglutide | 37 | $67,705 |
| ForteoTeriparatide | 11 | $42,673 |
| KerendiaFinerenone | 38 | $30,531 |
| ProliaDenosumab | 17 | $29,399 |
| JanuviaSitagliptin Phosphate | 19 | $27,953 |
| RybelsusSemaglutide | 24 | $22,281 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 36 | $21,297 |
| InvokanaCanagliflozin | 11 | $16,662 |
| Novolog FlexpenInsulin Aspart | 55 | $13,407 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $13,040 |
| FarxigaDapagliflozin Propanediol | 16 | $12,462 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Forteo, Humalog | $690 | $223,692160 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $1,221 | $154,678184 claims |
| Boehringer IngelheimJardiance | $430 | $127,579122 claims |
| BayerKerendia | $428 | $30,53138 claims |
| AmgenProlia | $347 | $29,39917 claims |
| MerckJanuvia | $184 | $27,95319 claims |
| AstraZenecaFarxiga | $295 | $12,46216 claims |
| AbbVieSynthroid | $129 | $5,53577 claims |
| IBSA Pharma Inc.Tirosint-Sol | $56 | $3,82114 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $23 | $2,075169 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Gulfport
- Stephanie RomeroGulfport$28K
- Ashley HouseGulfport$14K
- Chaeleena LaddGulfport$14K
- Justine HuntGulfport$12K
- Laura StevensGulfport$11K
- Cinda PerrymanFayette$888K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.